Search


Current filters:
Start a new search
Add filters:

Use filters to refine the search results.


Results 171-180 of 180 (Search time: 0.006 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2011Mutational analysis in chronic myeloid leukemia: When and what to do?Branford, S.; Hughes, T.
1997Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control.Hughes, T.; Grigg, A.; Szer, J.; Ho, J.; Ma, D.; Dale, B.; Green, R.; Norman, J.; Sage, R.; Herrmann, R.; Cannell, P.; Schwarer, A.; Taylor, K.; Atkinson, K.; Arthur, C.
1999Monitoring chronic myeloid leukaemia therapy by real time quantitative PCR in blood is a reliable alternative to bone marrow cytogeneticsBranford, S.; Hughes, T.; Rudzki, Z.
2013Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformationKok, C.; Watkins, D.; Leclercq, T.; D'Andrea, R.; Hughes, T.; White, D.
2013NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisisWatkins, D.; Hughes, T.; White, D.; D'Andrea, R.
1998Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cellsLewis, I.; McDiarmid, L.; Samels, L.; To, L.; Hughes, T.
2015KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategyYeung, D.; Tang, C.; Vidovic, L.; White, D.; Branford, S.; Hughes, T.; Yong, A.
2018Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the Phase IIIb ENESTswift studyHiwase, D.; Tan, P.; D'Rozario, J.; Taper, J.; Powell, A.; Irving, I.; Wright, M.; Branford, S.; Yeung, D.; Anderson, L.; Gervasio, O.; Levetan, C.; Roberts, W.; Solterbeck, A.; Traficante, R.; Hughes, T.
2019Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemiaRoss, D.; Pagani, I.; Irani, Y.; Clarson, J.; Leclercq, T.; Dang, P.; McLean, J.; Saunders, V.; Carne, L.; Reynolds, J.; Ritchie, D.; White, D.; Branford, S.; Hughes, T.; Yong, A.
2018Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell linesLu, L.; Kok, C.; Saunders, V.; Wang, J.; McLean, J.; Hughes, T.; White, D.; White, D.